Active Pharmaceutical Ingredient CDMO Market Projected to Reach $273.92 Billion by 2034
The global active pharmaceutical ingredients (API) contract development and manufacturing organization (CDMO) market is forecast to grow from $139.33 billion in 2025 to $273.92 billion by 2034, representing a compound annual growth rate (CAGR) of 7.8%, according to a new report from Nova One Advisor.
This expansion is driven by pharmaceutical companies increasingly partnering with CDMOs to address challenges in drug manufacturing, avoiding substantial capital expenditures for in-house facilities and staffing. CDMOs offer specialized expertise throughout the development and manufacturing process, including drug substance manufacturing, analytical testing, and regulatory compliance support. This trend is particularly important as the pharmaceutical industry focuses on increasingly complex therapies.
The Asia Pacific region currently dominates the API CDMO market, accounting for 39% of revenue in 2024, while the United States holds the largest share in North America. Within the market, synthetic APIs currently represent the largest segment at 74% of revenue, but the antibody-drug conjugate segment is expected to experience significant growth. Recent activity includes Sun Nuclear’s acquisition of Oncospace in April 2025, demonstrating a commitment to leveraging technology to improve treatment outcomes, and a partnership between Phlow Corp. and Antheia to onshore essential medicine production in the U.S. For more information on pharmaceutical manufacturing, visit the Food and Drug Administration website.
Looking ahead, the clinical manufacturing segment is expected to see rapid growth, and companies are increasingly adopting sustainable practices like single-use bioreactors and continuous flow manufacturing to reduce waste and improve efficiency. Nova One Advisor’s full report, including detailed segmentation analysis, is available here. Officials anticipate continued investment in CDMO capabilities to meet the growing demand for both innovative and generic drugs.
